Shares of Indaptus Therapeutics Inc. were up 21.6% in premarket trading on Thursday after the company said U.S. regulators have allowed a Phase 1 clinical trial for its experimental cancer treatment to move forward. Indaptus plans to enroll patients with advanced solid tumors who have already unsucessfully undergone approved treatments. The study is set to begin in the second half of the year. Indaptus stock has tumbled 56.1% this year, while the S&P 500 has declined 17.7%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
